Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
- PMID: 9168977
- DOI: 10.1006/bbrc.1997.6603
Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis
Abstract
A factor which inhibits osteoclast-like cell formation was found in the conditioned medium of human embryonic lung fibroblasts, IMR-90. The factor, termed osteoclastogenesis inhibitory factor, OCIF, was purified to homogeneity. OCIF is a heparin-binding basic glycoprotein and has been isolated as a monomer with an apparent molecular weight (Mr) of 60,000 and a homodimer with a Mr of 120,000. The N-terminus of OCIF is blocked and the determination of internal amino acid sequences revealed that OCIF has no homology to known proteins. OCIF inhibited in a dose-dependent manner osteoclastogenesis elicited through three distinct signaling pathways stimulated by 1 alpha,25-dihydroxy vitamin D3, parathyroid hormone, and interleukin-11, respectively, in a dose range of 1 to 40 ng/ml (IC50 = 4 to 6 ng/ml). OCIF neither inhibits bone resorption by mature osteoclasts nor exerts any other biological activities. These data strongly suggest that OCIF is a novel cytokine which specifically inhibits osteoclastogenesis.
Similar articles
-
[Osteoclastogenesis inhibitory factor (OCIF)/OPG].Nihon Rinsho. 1998 Jun;56(6):1435-9. Nihon Rinsho. 1998. PMID: 9648461 Review. Japanese.
-
Osteoclast differentiation factor mediates an essential signal for bone resorption induced by 1 alpha,25-dihydroxyvitamin D3, prostaglandin E2, or parathyroid hormone in the microenvironment of bone.Biochem Biophys Res Commun. 1998 May 19;246(2):337-41. doi: 10.1006/bbrc.1998.8610. Biochem Biophys Res Commun. 1998. PMID: 9610359
-
Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro.Endocrinology. 1998 Mar;139(3):1329-37. doi: 10.1210/endo.139.3.5837. Endocrinology. 1998. PMID: 9492069
-
Osteoclastogenesis inhibitory factor (OCIF) directly inhibits bone-resorbing activity of isolated mature osteoclasts.Biochem Biophys Res Commun. 1998 Oct 29;251(3):796-801. doi: 10.1006/bbrc.1998.9523. Biochem Biophys Res Commun. 1998. PMID: 9790989
-
The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption.J Bone Miner Res. 2000 Jan;15(1):2-12. doi: 10.1359/jbmr.2000.15.1.2. J Bone Miner Res. 2000. PMID: 10646108 Review.
Cited by
-
Novel comb-shaped PEG modification enhances the osteoclastic inhibitory effect and bone delivery of osteoprotegerin after intravenous administration in ovariectomized rats.Pharm Res. 2012 Nov;29(11):3143-55. doi: 10.1007/s11095-012-0807-4. Epub 2012 Jun 23. Pharm Res. 2012. PMID: 22729371
-
RANKL/OPG; Critical role in bone physiology.Rev Endocr Metab Disord. 2015 Jun;16(2):131-9. doi: 10.1007/s11154-014-9308-6. Rev Endocr Metab Disord. 2015. PMID: 25557611 Review.
-
Mammary gland-specific expression of biologically active human osteoprotegerin in transgenic mice.Dev Reprod. 2013 Mar;17(1):1-8. doi: 10.12717/DR.2013.17.1.001. Dev Reprod. 2013. PMID: 25949115 Free PMC article.
-
Receptor-Activator of Nuclear KappaB Ligand Expression as a New Therapeutic Target in Primary Bone Tumors.PLoS One. 2016 May 10;11(5):e0154680. doi: 10.1371/journal.pone.0154680. eCollection 2016. PLoS One. 2016. PMID: 27163152 Free PMC article.
-
Giant cell tumour of the bone treated with denosumab: How has the blood supply and oncological prognosis of the tumour changed?J Orthop Translat. 2018 Nov 7;18:100-108. doi: 10.1016/j.jot.2018.10.003. eCollection 2019 Jul. J Orthop Translat. 2018. PMID: 31508313 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials